

One-pot three-component double-click method for synthesis of $[^{67}\text{Cu}]$ -labeled biomolecular radiotherapeutics[†]

K. Fujiki,^{*1} S. Yano,^{*2} T. Ito,^{*3} Y. Kumagai,^{*3} Y. Murakami,^{*3} O. Kamigaito,^{*2} H. Haba,^{*2} and K. Tanaka^{*1,*4,*5}

A one-pot three-component double-click process to prepare tumor-targeting agents for cancer radiotherapy is described here. By utilizing DOTA (or NOTA) containing tetrazines (DOTA: 1, 4, 7, 10-tetraazadodecane-1, 4, 7, 10-tetraacetic acid, NOTA: 1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid) and the TCO-substituted aldehyde (TCO: trans-cyclooctene), the two click reactions, the tetrazine ligation (an inverse electron-demand Diels-Alder cycloaddition)¹⁾ and the RIKEN click (a rapid 6π -azaelectrocyclization),²⁻⁸⁾ could simultaneously proceed under mild conditions to afford the covalent attachment of the DOTA or NOTA, which forms a bioavailable stable complex with copper (II), to biomolecules such as albumin and anti-IGSF4 antibody without altering their activities (Fig. 1).

Subsequently, the radiolabeling of DOTA- or NOTA-attached albumin and anti-IGSF4 antibody (a tumor-targeting antibody) with ^{67}Cu as a promising β^-/γ -emitting theranostic radionuclide having a half-life of

62 h, which is compatible with radioimmunotherapy, could be achieved by mixing DOTA- or NOTA-attached albumin and anti-IGSF4 antibody with RIs and subsequent purification by Amicon filtration; a separate experiment with ^{65}Zn was conducted for comparison (Fig. 2 and Table 1). ^{67}Cu and ^{65}Zn could be produced in the $^{70}\text{Zn}(d,\alpha n)^{67}\text{Cu}$ and $^{nat}\text{Cu}(d,x)^{65}\text{Zn}$ reactions at the AVF cyclotron. Our work provides a new and operationally simple method for introducing ^{67}Cu to biomolecules, which is an important process for preparing clinically relevant tumor-targeting agents.




Fig. 2. Radiolabelings of DOTA or NOTA-attached albumins and anti-IGSF4 antibody.




Fig. 1. (a) One-pot three-component click labeling of albumin and anti-IGSF4 antibody as a cancer-targeting agent. (b) Affinities of intact and labeled anti-IGSF4 antibodies to IGSF4 analyzed by ELISA. DMF = N,N-dimethyl formamide, ELISA = enzyme-linked immunosorbent assay.

[†] Condensed from the article in *Sci. Rep.* **7**, 1912 (2017)

^{*1} Biofunctional Synthetic Chemistry Laboratory, RIKEN

^{*2} RIKEN Nishina Center

^{*3} The Institute of Medical Science, University of Tokyo

^{*4} Biofunctional Chemistry Laboratory, Kazan Federal University

^{*5} JST-PRESTO

Table 1. Radiochemical yields (RCY) of ^{67}Cu and ^{65}Zn .

Entry	Chelator-attached biomolecules	Added [^{65}Zn] or [^{67}Cu] ^a (Radioactivities)	RCY ^b (%)
1	DOTA-albumin 7b	[^{65}Zn] (300 kBq)	80
2	DOTA-albumin 7b	[^{67}Cu] (11 MBq)	72
3	DOTA-anti-IGSF4 mAb 9a	[^{67}Cu] (11 MBq)	51
4	NOTA-albumin 8	[^{67}Cu] (11 MBq)	19
5	NOTA-anti-IGSF4 mAb 9b	[^{67}Cu] (11 MBq)	7

^a) Specific activities of ^{67}Cu and ^{65}Zn were 110 MBq/ μg and 125 MBq/ μg , respectively.

^b) RCY (Radiochemical yield) was obtained from the radioactivity of the purified radiolabeled product against the added [^{65}Zn] or [^{67}Cu].

References

- 1) M. L. Blackman, M. Royzen, J. M. Fox, *J. Am. Chem. Soc.* **130**, 13518 (2008).
- 2) K. Tanaka *et al.*, *Angew. Chem. Int. Ed.* **47**, 102 (2008).
- 3) K. Tanaka *et al.*, *Angew. Chem. Int. Ed.* **49**, 8195 (2010).
- 4) K. Fukase, K. Tanaka, *Curr. Opin. Chem. Biol.* **16**, 614 (2012).
- 5) K. Tanaka *et al.*, *J. Org. Chem.* **66**, 3099 (2001).
- 6) K. Tanaka, S. Katsumura, *J. Am. Chem. Soc.* **124**, 9660 (2002).
- 7) K. Tanaka *et al.*, *J. Org. Chem.* **69**, 5906 (2004).
- 8) K. Fujiki, K. Tanaka, *e-EROS Encyclopedia of Reagents for Organic Synthesis* (Wiley, 2018) in press.